ReviewNature reviews. Endocrinology2013
Diagnosis and management of Graves disease: a global overview.
Review in Nature reviews. Endocrinology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 136 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
136 citing papers in PubMed, 5 syntheses or guidelines pooled it, 290 citations in OpenAlex.
- 2025 Korean Thyroid Association Management Guidelines for Radioactive Iodine Therapy in Patients with Hyperthyroidism.Endocrinology and metabolism (Seoul, Korea) · 2025Guideline
- Long-term outcome of treatments for Graves disease in the children and adolescent population.Endocrine · 2023Pooled it
- Change in newly diagnosed Graves' disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression.Journal of endocrinological investigation · 2021Pooled it
- Serum TSH level as predictor of Graves' disease recurrence following antithyroid drug withdrawal: A systematic review.PloS one · 2021Pooled it
- Association of polymorphisms of rs179247 and rs12101255 in thyroid stimulating hormone receptor intron 1 with an increased risk of Graves' disease: A meta-analysis.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2016Pooled it
- Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves' Disease Hyperthyroidism During Methimazole Treatment.Frontiers in endocrinology · 2022Trial
- Intraorbital injection of rituximab versus high dose of systemic glucocorticoids in the treatment of thyroid-associated orbitopathy.Endocrine · 2015Trial
- Gut and Orbital Dysbiosis Associated with Graves' Disease and Graves' Orbitopathy: A Systematic Review.Journal of clinical medicine · 2026Review
- Treatment outcomes in patients with relapsed Graves' disease.Archives of endocrinology and metabolism · 2026Article
- Clinical utility of TRAb reduction in predicting remission in pediatric Graves' disease.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2026Article
- The public health burden of diabetes mellitus and thyroid disease: twin epidemics.Nature reviews. Endocrinology · 2026Review
- Clinical Evaluation of a New Automated Bridge Assay for the Detection of Thyroid-Stimulating Hormone Receptor Autoantibodies.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2026Article
- TSHR-Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Integrative analysis of gut microbiota, plasma metabolome, and gene expression identifies causal mediators in Graves' disease pathogenesis.Frontiers in microbiology · 2026Article
- Integrated RNA-seq and sQTL analysis reveal immune and splicing regulatory features underlying relapse and remission after treatment of Graves' disease.Frontiers in endocrinology · 2026Article
- The multiple functions of CD5 in diseases related to immune disorders.Annals of medicine · 2025Review
- Early effects of radioactive iodine (I-131) therapy on liver function in patients with Graves' disease: a 48-h analysis.BMC research notes · 2025Article
- Effect of radioiodine treatment for Graves' disease on the generation of TSH anti-receptor stimulating antibodies (TSI).Archives of endocrinology and metabolism · 2025Article
- Establishment of Time-Resolved Fluorescence Immunoassay for Thyrotropin Receptor Antibodies and Clinical Application.Journal of fluorescence · 2025Article
- Sex-Related Differences in Risk Factors Associated With Nonhealing or Recurrence of Hyperthyroidism in Patients With Graves' Disease Treated With Radioactive Iodine.Health care science · 2025Article
76 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graves disease is an autoimmune disorder characterized by goitre, hyperthyroidism and, in 25% of patients, Graves ophthalmopathy. The hyperthyroidism is caused by thyroid hypertrophy and stimulation of function, resulting from interaction of anti-TSH-receptor antibodies (TRAb) with the TSH receptor on thyroid follicular cells. Measurements of serum levels of TRAb and thyroid ultrasonography represent the most important diagnostic tests for Graves disease. Management of the condition currently relies on antithyroid drugs, which mainly inhibit thyroid hormone synthesis, or ablative treatments ((131)I-radiotherapy or thyroidectomy) that remove or decrease thyroid tissue. None of these treatments targets the disease process, and patients with treated Graves disease consequently experience either a high rate of recurrence, if receiving antithyroid drugs, or lifelong hypothyroidism, after ablative therapy. Geographical differences in the use of these therapies exist, partially owing to the availability of skilled thyroid surgeons and suitable nuclear medicine units. Novel agents that might act on the disease process are currently under evaluation in preclinical or clinical studies, but evidence of their efficacy and safety is lacking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.